Helix Biopharma Announces Upcoming Poster Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Helix BioPharma Corp.

Toronto, Ontario – TheNewswire – October 10, 2023 – Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), an immune-oncology antibody-drug-conjugate company developing an innovative drug platform for the treatment of cancer, announced today that the Company will present new preclinical data on L-DOS47 in combination with PD1 checkpoint inhibition at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in the Hynes Convention Center, Boston, via in person attendance, October 11-15, 2023.


Poster Presentation Details:

Title: Neutralizing Acidosis with ADC L-DOS47 Urease Immunoconjugate Enhances Response to Anti-PD1 Checkpoint Blockade in A Preclinical Orthotopic Model of Pancreatic Adenocarcinoma

Abstract Number: 35494

Poster Presentation Date and Time: Friday, October 13, 12:30 pm – 4:00 pm

Location: Level 2, Exhibit Hall D

Poster Session B, Poster Number: B125


During the conference, Helix will highlight the enhanced effects of anti-PD1 immunotherapy when combined with L-DOS47 in an orthotopic Pancreatic tumor model in mice. The drug has already been administered to over 120 patients in the clinic across 4 clinical trials and has been shown to be safe and well tolerated. Additionally, L-DOS47 has also demonstrated promising anti-tumor activity across a range of doses, both as monotherapy and in combination with chemotherapy agents. The Company is open to collaborating with the right partner(s) to explore potential synergies with anti-PD1 and other treatment regimens.  


“We are enthusiastic about the results of these studies, which showcase a distinctive ADC platform. This platform has the capability to synergize effectively with a wide range of approaches, such as chemotherapy, radiation therapy, immunotherapy, and emerging cell therapies. This synergy aims to boost effectiveness while minimizing safety issues.” said Jacek Antas, Helix’s Chief Executive Officer.


More details about the AACR-NCI-EORTC Conference are available on the official website. Full text of the abstracts is now available on their website.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47. Helix is listed on the TSX under the symbol “HBP”.

About DOS47

DOS47 is based upon a naturally occurring enzyme isolated from the jack-bean plant called urease that breaks down a natural substance found in the body, urea, into metabolites that include ammonia and hydroxyl ions. By doing so at the site of cancerous tissues in the body, the Company believes DOS47 can modify the microenvironmental condition surrounding cancerous cells in a manner that leads to cancer cell death. DOS47 increases the pH of the tumor microenvironment, effectively reversing the acidic extracellular conditions that are believed to promote persistence of tumor cells and disable immune cells. Raising the pH of the tumor microenvironment helps to reactivate immune cells enhancing their ability to kill cancer.  DOS47 is a platform with which to build targeted antibody-drug conjugates.


About L-DOS47

L-DOS47 is Helix’s first targeted antibody-drug conjugate that uses an anti-CEACAM6 camelid antibody to localize to CEACAM6-expressing tumors. Its design is an innovative approach to neutralize the acidic pH in the tumor microenvironment surrounding cancer cells in a manner that leads to their destruction.

For more information, please contact:

Helix BioPharma Corp.
Suite 2704, 401 Bay Street
Toronto, Ontario, M5H 2Y4
Tel: 905-841-2300
Namrata Malhotra, Corporate Secretary [email protected]

Forward-Looking Statements and Risks and Uncertainties

This news release contains forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions, and expectations with respect to the Company’s future business, operations, research, and development, including the Company’s activities relating to DOS47. Forward-looking statements can further be identified by the use of forward-looking terminology such as “ongoing”, “estimates”, “expects”, or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could”, or “should” occur or be achieved, or comparable terminology referring to future events or results.

Forward-looking statements are statements about the future and are inherently uncertain and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward- looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements, including financial outlooks, are intended to provide information about management’s current plans and expectations regarding future operations, including without limitation, future financing requirements, and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release.

The Company’s actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including without limitation; the risk that the Company’s assumptions may prove to be incorrect; the risk that additional financing may not be obtainable in a timely manner, or at all, and that clinical trials may not commence or complete within anticipated timelines or the anticipated budget or may fail; third party suppliers of necessary services or of drug product and other materials may fail to perform or be unwilling or unable to supply the Company, which could cause delay or cancellation of the Company’s research and development activities; necessary regulatory approvals may not be granted or may be withdrawn; the Company may not be able to secure necessary strategic partner support; general economic conditions, intellectual property and insurance risks; changes in business strategy or plans; and other risks and uncertainties referred to elsewhere in this news release, any of which could cause actual results to vary materially from current results or the Company’s anticipated future results. Certain of these risks and uncertainties, and others affecting the Company, are more fully described in the Company’s annual management’s discussion and analysis for the year ended July 31, 2022, under the heading “Risks and Uncertainties” and Helix’s Annual Information Form, in particular under the headings “Forward-looking Statements” and “Risk Factors”, and other reports filed under the Company’s profile on SEDAR at www.sedar.com from time to time. Forward-looking statements and information are based on the beliefs, assumptions, opinions, and expectations of Helix’s management on the date of this new release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required.


Copyright (c) 2023 TheNewswire – All rights reserved.

Comments are closed.

Free newsletter for stock pics, interview transcripts & investing ideas